<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767974</url>
  </required_header>
  <id_info>
    <org_study_id>ISSIRES0066</org_study_id>
    <nct_id>NCT01767974</nct_id>
  </id_info>
  <brief_title>Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer</brief_title>
  <acronym>SPACE</acronym>
  <official_title>Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be
      performed. The detection rates of EGFR mutation will be compared using paired samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single arm, open label, prospective, observational study of gefitinib treatment for locally
      advanced (stage IIIB) or IV (metastatic) or relapsed NSCLC patients.

      Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be
      performed. The detection rates of EGFR mutation will be compared using paired samples.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of EGFR mutation</measure>
    <time_frame>two weeks</time_frame>
    <description>To prove higher detection rate of EGFR mutation with PNA clamping compared with sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verification of PNA positive casese</measure>
    <time_frame>Two weeks</time_frame>
    <description>To analyze the Sequencing negative/PNA clamping positive group (where sample is available) with another sensitive technique COBAS test</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Non-Small Cell Lung Cancer</arm_group_label>
    <description>Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from lung cancer tumor tissue obtained by bronchoscopy, needle biopsy or surgical
      resection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced stage IIIB not suitable for curative therapy or stage IV (metastatic)
             disease or relapsed NSCLC

          -  ECOG Performance status 0~2.

          -  Written Informed Consent

          -  Female or male patients aged 18 years or over, eligible for treatment for NSCLC

        Exclusion Criteria:

          -  Previous exposure to EGFR-TKI

          -  Concomitant use of other anti-cancer drugs with EGFR-TKI

          -  Patients without available Tumor DNA

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the subject to participate in the study

          -  Pregnancy or breast-feeding women (women of childÂ¬bearing potential). Women of
             childbearing potential must practice acceptable methods of birth control to prevent
             pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <phone>82-61-379-7614</phone>
    <email>kyc0923@jnu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ju-Mi Yoon, MS</last_name>
    <phone>82-61-379-7861</phone>
    <email>hhw55@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-Gun</city>
        <state>Jeonnam</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Chul Kim, MD, PhD</last_name>
      <phone>82-61-379-7614</phone>
      <email>kyc0923@jnu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ju-Mi Yoon, MS</last_name>
      <phone>82-61-379-7861</phone>
      <email>hhw55@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu-Sik Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>In-Jae Oh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-Small Cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 13, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>July 20, 2015</submitted>
    <returned>August 14, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

